Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Stoke Therapeutics Inc (NASDAQ: STOK) was $26.1 for the day, down -13.12% from the previous closing price of $30.04. In other words, the price has decreased by -$13.12 from its previous closing price. On the day, 2.25 million shares were traded. STOK stock price reached its highest trading level at $29.38 during the session, while it also had its lowest trading level at $24.5.
Ratios:
Our analysis of STOK’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.77 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.39. For the most recent quarter (mrq), Quick Ratio is recorded 6.98 and its Current Ratio is at 6.98. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Jefferies on July 18, 2025, initiated with a Buy rating and assigned the stock a target price of $30.
On December 20, 2024, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $24.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 03 ’25 when BARUCH TICHO bought 5,931 shares for $30.04 per share.
Kaye Edward M. MD sold 25,000 shares of STOK for $750,000 on Oct 08 ’25. The Director now owns 49,124 shares after completing the transaction at $30.00 per share. On Oct 08 ’25, another insider, EDWARD M KAYE, who serves as the Director of the company, bought 25,000 shares for $27.31 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, STOK now has a Market Capitalization of 1430212608 and an Enterprise Value of 1186055552. As of this moment, Stoke’s Price-to-Earnings (P/E) ratio for their current fiscal year is 30.89. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.15 while its Price-to-Book (P/B) ratio in mrq is 4.26. Its current Enterprise Value per Revenue stands at 5.933 whereas that against EBITDA is 28.058.
Stock Price History:
The Beta on a monthly basis for STOK is 1.32, which has changed by 1.3019156 over the last 52 weeks, in comparison to a change of 0.18286073 over the same period for the S&P500. Over the past 52 weeks, STOK has reached a high of $38.69, while it has fallen to a 52-week low of $5.35. The 50-Day Moving Average of the stock is -0.16%, while the 200-Day Moving Average is calculated to be 81.00%.
Shares Statistics:
STOK traded an average of 1.11M shares per day over the past three months and 930240 shares per day over the past ten days. A total of 54.72M shares are outstanding, with a floating share count of 47.09M. Insiders hold about 14.06% of the company’s shares, while institutions hold 113.35% stake in the company. Shares short for STOK as of 1760486400 were 10831308 with a Short Ratio of 9.72, compared to 1757894400 on 11386332. Therefore, it implies a Short% of Shares Outstanding of 10831308 and a Short% of Float of 23.9.
Earnings Estimates
As of right now, 9.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.63, with high estimates of -$0.54 and low estimates of -$0.81.
Analysts are recommending an EPS of between $0.48 and -$0.1 for the fiscal current year, implying an average EPS of $0.31. EPS for the following year is -$2.89, with 9.0 analysts recommending between -$2.3 and -$3.65.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 9 analysts. It ranges from a high estimate of $12M to a low estimate of $3M. As of. The current estimate, Stoke Therapeutics Inc’s year-ago sales were $4.89MFor the next quarter, 9 analysts are estimating revenue of $4.86M. There is a high estimate of $6.3M for the next quarter, whereas the lowest estimate is $3M.
A total of 11 analysts have provided revenue estimates for STOK’s current fiscal year. The highest revenue estimate was $205.8M, while the lowest revenue estimate was $178.39M, resulting in an average revenue estimate of $186.16M. In the same quarter a year ago, actual revenue was $36.55M
